ALX Oncology Holdings (NASDAQ: ALXO) has announced the appointment of board member Barbara Klencke, MD, as interim chief medical officer, (CMO).
According to ALX, Dr. Alan Sandler is departing from the role of CMO and will return to his former position on the ALX Oncology BOD, where he previously served.
In a statement, Jason Lettmann, CEO of ALX, commented, “Dr. Barbara Klencke’s extensive expertise in driving cancer innovation is evidenced by her substantial contributions to the development and approval of numerous first-in-class therapies, making her well positioned to lead the execution of our company’s near and longer-term milestones. As a current member of our BOD, she can immediately step into the Interim CMO role to implement our focused development strategy across both the evorpacept and ALX2004 clinical programs. Barbara brings a track record of success with early-stage companies having served as the CMO of Sierra Oncology from 2015 through its acquisition by GlaxoSmithKline in 2022. We also thank Alan for his instrumental role as CMO and look forward to his continued contributions to the company as he returns to his role as a Director on our board.”
